·
Biotech company focused on production of cutting-edge industrial
hemp, cannabis/cannabidiol (CBD) products
·
R&D efforts include nutraceuticals, pharmaceuticals,
bioceuticals, phytoceuticals and cosmeceuticals catering to health, wellness
and alternative medicine markets
·
International provisional patent application targets CBD’s
powerful medicinal benefits
·
Integration of CBD molecule with generic drug molecules opens
new medical frontier
·
U.S. consumer market for cannabinoid-based pharmaceuticals
estimated at $50 billion by 2029
·
Medical diagnostic device MSN-2 slated for clinical tests to
validate detection of various STDs
·
Global market for diagnostic testing of STDs expected to reach
$108.5 billion by 2019
Earth Science Tech,
Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields
of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device
research and development. Earth Science Tech offers the highest purity and
quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market.
Made using the supercritical CO2 liquid extraction process, the company’s CBD
oil is 100 percent natural and organic. Earth Science Tech has partnered with
the University of Central Oklahoma and DV Biologics Laboratory to conduct
research and development projects that scientifically support and advance the
healthcare benefits of its high-grade hemp CBD oil.
Earth Science Tech
Inc. currently has three wholly owned subsidiaries focused on developing its
role as a world leader in the CBD space and expanding its work in the
pharmaceutical and medical device sectors. These subsidiaries include:
·
Earth Science Pharma, Inc., which is committed to development of
low cost, noninvasive diagnostic tools, medical devices, testing processes and
vaccines for sexually transmitted infections and/or diseases. Earth Science
Pharmaceutical CEO and chief science officer Michel Aubé is leading the
company’s research and development efforts. The company’s first medical device,
MSN-2, is a home kit designed for the detection of STIs, such as chlamydia,
from a self-obtained gynecological specimen. Earth Science Pharma is working to
develop and bring to market medical devices and vaccines that meet the specific
needs of women.
·
Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a
leadership role in the development of new, leading-edge, cannabinoid-based
pharmaceutical and nutraceutical products. CTI is invested in research and
development to explore and harness the medicinal power of cannabidiol. The
company holds a provisional application patent for a CBD product that is
focused on developing treatments for breast and ovarian cancers.
·
KannaBidioiD (“KBD”) provides a wide variety of products geared
toward the recreational space of cannabis. KBD’s unique Kanna and CBD
formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids
products. Kanna and CBD synergistically enhance one another, providing optimal
relaxation, an uplifting sensation, enhanced focus and the added benefit of
assisting with nicotine reduction therapy.
Earth Science Tech
celebrated a significant, developmental year during 2017 by sharing its
achievements in a condensed end-of-year report. Among the report’s highlights
are the implementation of a development plan for the coming three years, which
includes expanding into Canada and opening new manufacturing and shipping
facilities. Of particular interest is the acquisition of Canna Inno
Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which
gives Earth Science Tech access to Canadian government grants offered to
innovators in the pharmaceutical industry. ETST has also launched development
of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat
various forms of breast cancer.
In October 2017, ETST
announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship
Clinic) for a mini-clinical trial, the last trial needed before the MSN-2
device, designed for the detection of STIs, enters molecular diagnostic trials.
And in November 2017, the company began pre-launch human trials on a new CBD
formula to fight against the U.S. opioid epidemic. The new formula, expected to
decrease cravings and the negative effects of withdrawal in addicts, is based
on industrial hemp CBD mixed with a known natural ingredient proven to help
increase dopamine levels. ETST’s medical devices will first be launched in
Vietnam, Djibouti and Morocco while the company awaits regulatory permission to
enter the North American market.
The company expects to
up-list to the OTCQB in early 2018, which management believes will attract
well-funded institutional investors and pave the way to becoming the next
billion-dollar-in-capitalization company on the OTC markets. Other highlights
include completion of the company’s Scientific Advisory Council with a team of
recognized scientists, the launching of several CBD-infused edible products and
entry into the medical devices market through collaborative partnerships.
Earth Science Tech has
signed a collaborate agreement with Laboratories BNK Canada, a private
laboratory that will conduct the clinical studies necessary for MSN-2 medical
device-related services to meet regulatory requirements. ETST has confirmed the
MSN-2 device’s ability to detect chlamydia, and is working to validate similar
results for gonorrhea, both highly infectious diseases that often have
permanent consequences for patients. ETST will also add testing for
trichomoniasis and a complete body fluid panel to detect the different
serotypes of the human papillomavirus (HPV) that causes cervical cancer. These
additions will help the company create sales opportunities in the global market
for diagnostic testing of STDs that Transparency Market Research has indicated
will grow to $108 billion by 2019.
Cannabis Therapeutics
is in the development stage of two cannabinoid-based pharmaceutical drugs and
three cannabinoid-based nutraceutical products targeting a variety of ailments
such as anxiety, depression, triple negative breast cancer, and fatty liver
disease, among others. Research into the benefits of the non-psychoactive
cannabinoid molecules found in the cannabis plant is supported by ETST’s
International Application for Provisional Patent titled “Cannabidiol
Compositions Including Mixtures and Uses Thereof,” which was filed on October
8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing
CBD-based drugs and nutraceutical products and in working to integrate the CBD
molecule with existing generic drug molecules to create more efficient
medications with fewer and less severe side effects. A report in Hemp Business
Journal predicts the CBD consumer market will grow to $2.1 billion by 2020,
while other industry experts expect an increase to almost $3 billion by 2021. A
recent report by Statista projects the U.S. consumer market for
cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.
The management team at
Earth Science Tech brings decades of invaluable experience to the
nutraceutical, dietary supplement field as well as the life sciences sectors.
Nickolas S. Tabraue, who serves as the president, director and chief operating
officer, is an industry veteran with extensive knowledge of supplements, retail
management, customer service and sales expertise. He is joined by CEO and CSO
Dr. Michel Aubé, a microbiologist whose scientific research in sexually
transmitted infections, cancer and stem cell biology has been widely published
in several prestigious medical journals. Sergio Castillo, chief marketing
officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing
and sales experience to Earth Science Tech, which is complemented by Issa
El-Cheikh, Ph.D., and his 25 years in the international finance, accounting,
planning and execution of large scale transactions in the public and private
sectors.
Earth Science Tech’s
products include CBD, a natural constituent of hemp oil derived from hemp stalk
and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals,
personal care products, homeopathies, functional foods and other products
delivered in such forms as capsules, tablets, soft gels, chewables, liquids,
creams, sprays, powders and whole herbs. Earth Science products can be found at
retail stores throughout the United States and are available for purchase
through the internet.
For
more information, visit the company’s website at www.EarthScienceTech.com
About
MissionIR
MissionIR
is primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For
more information, visit www.MissionIR.com
MissionIR
(MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please
see full terms of use and disclaimers on the Mission Investor Relations website
applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
